FleX technology (Flex 1.0, Schnütgen et al., 2003) is used to create an inducible point mutation in a gene: the gene mutation can be induced in a temporal- and tissue- specific manner from its endogenous locus. The classical FleX technology has been improved (Flex 2.0 patent pending M.C. Birling and J. Chelly) and allows now to generate any conditional point mutation.
- Bypasses lethal phenotype associated with the mutation expression.
- Analysis of gene mutation effects on adult animal (pathologies that normally occurs on adulthood).
- Study of effects of non-mutated gene function restauration (degenerative pathologies).
- Developed by our lab to achieve conditional SNP (single-nucleotide polymorphism) model.
- Model design is complex to ensure that gene expression and patterns will remain unchanged.
- Flex 1.0 is not working to achieve conditional SNP model.
- The Flex technology was developed by Pr. Chambon and Dr. Ghyselinck at the Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC, France) which scientific experts closely interact and work with PHENOMIN. The technology license is held by PHENOMIN supervisory administrations (CNRS, INSERM, University of Strasbourg).
- Flex 2.0 has been developed by Dr. Birling and Pr. Chelly at the Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC) & PHENOMIN-ICS.
- Personalized genome engineering service to fit our customer needs.
- Implication in international consortia (near 20 different consortia) to benefit from the last technics and scientific expertise.
- Continuous R&D activity to improve our technics and success rate and propose our customers the best approach for their projects.